NCT07161037View on ClinicalTrials.gov

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

July 22, 2027

Study Completion Date

December 31, 2027

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
DRUG

VX-407

Tablets for oral administration.

Trial Locations (4)

31904

RECRUITING

Renal Associates, Columbus

35007

RECRUITING

Alabama Kidney Research, Alabaster

89107

RECRUITING

DaVita Kidney Care - Las Vegas, Las Vegas

06762

RECRUITING

Nephrology & Hypertension Associates, PC, Middlebury

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY